Navigation Links
The CementBloc and Novartis Vaccines to Jointly Present Top Considerations in Interactive Selling at the 11th Annual iPharmaConnect

NEW YORK, March 21, 2012 /PRNewswire/ -- Meghan Lopresto, VP, Sales Force Automation Analytics at The CementBloc, and Emad Abdelnaby, Director of Marketing at Novartis Vaccines, will be co-presenting their expertise in interactive selling at CBI's iPharmaConnect plenary session on March 27, 2012, in Philadelphia.

The conference is a 3-day symposium that will unite senior-level marketing, digital, brand, and medical affairs professionals to discuss novel approaches to thriving multichannel digital campaigns. From the client and agency perspectives, Ms. Lopresto and Mr. Abdelnaby will be presenting the success story behind the recently rolled-out program at Novartis Vaccines. Their talk, entitled, "Develop a Road Map for Transforming Your Organization Through Interactive Selling" will serve as an essential blueprint for optimizing iPad selling across an organization. 

"Transitioning your field sales team over to an iPad platform is more than just an upgrade of their technology," says Ms. Lopresto. "It represents a key shift in the engagement between sales representatives and their customers. A successful rollout of these new tools requires a defined road map of the process, including agreed-upon core principles and buy-in from multiple stakeholders. If this is achieved, an organization can be transformed, for the better, through interactive selling."

At The CementBloc, Ms. Lopresto plays a key role in interactive selling tool development and measurement, multichannel marketing planning and analytics, promotional spend optimization, CRM/PRM, and closed-loop marketing initiatives. For more than 10 years, Meghan has been in the pharmaceutical industry in leadership roles, providing clients with innovative solutions for multichannel and professional advertising campaigns. 

As Director of Marketing for the US Meningococcal Franchise at Novartis Vaccines and Diagnostics (NVD), Mr. Abdelnaby has responsibility for the development of professionally directed strategies and resources. Through his work at Novartis, Mr. Abdelnaby has helped to continue NVD's commitment to innovation in this space, including adoption of a broad-scale iPad platform for physician detailing, CRM, and sales training. 

For more information or to register for iPharmaConnect, please contact CBI at 1-800-817-8601.

About The CementBloc: The CementBloc is a leading multichannel health and wellness creative agency based in New York. Founded in 2000 by Susan Miller and Rico Viray, The CementBloc is also a founding member of Indigenus, an independent global network of entrepreneurial healthcare creative agencies.

SOURCE The CementBloc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ira Haimowitz, PhD, EVP, Group Director, Intelligence and Analytics at The CementBloc, to Present at Aberdeen Group Inaugural Business Analytics Summit
2. Ira Haimowitz, PhD, EVP, at The CementBloc, to Present on Best Practices in iPad Interactive Selling at 11th Annual ePharma Summit™
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
8. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
9. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
10. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
11. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):